posted on 2007-01-16, 00:00authored byMaría M. García-Alai, Karina I. Dantur, Clara Smal, Lía Pietrasanta, Gonzalo de Prat-Gay
The E6 oncoproteins of high-risk HPV types 16 and 18 are involved in the development of
cervical cancer. Besides its determinant role in carcinogenic progression, HPV E6 oncoprotein has also
been instrumental in elucidating fundamental aspects of p53 function and its ubiquitin−proteasome
degradation, with counterpart activities in various DNA tumor viruses. Establishing the conformational
state and cellular distribution unequivocally for the endogenous protein in HPV-transformed cell lines
derived from carcinomas is essential for understanding the underlying mechanism. Recombinant E6 from
high-risk strains 16 and 18 folds into soluble oligomers of ∼1.2 MDa, which are thermostable and display
cooperative loss of tertiary and secondary structure upon chemical denaturation. Antibodies raised against
these assemblies locate E6 evenly distributed in the cells. By depleting the polyclonal serum by
immunoblocking with monomeric E6, the nuclei of Hela and CaSki cells become completely devoid of
label, indicating that monomeric species are mainly localized in the nucleus and that both monomers and
oligomers share epitopes. The monomeric species promote degradation of p53 by the proteasome, which
correlates with the nuclear localization we describe. In contrast, the oligomeric E6 does not promote p53
degradation, in agreement with its cytoplasmic localization inferred from the immunoneutralization
experiments. Our results indicate that the cytoplasmic species contain conformational epitopes that may
arise from yet undefined homo or hetero-oligomers, but its localization otherwise agrees with that of the
other group of major E6 targets, those involving PDZ binding domains, which requires further investigation.